Superworth

Recursion Pharmaceuticals EPS RXRX

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$1.04
Latest quarter, Q2 FY26
−$0.25
Fiscal year 2025
−$1.48

Recursion Pharmaceuticals' earnings per share was −$1.04 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.25.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.48n/a
FY2024−$1.66n/a
FY2023−$1.57n/a
FY2022−$1.37n/a
FY2021−$2.30n/a
FY2020−$3.99n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.25n/a−$1.04
Q1 FY26−$0.22n/a−$1.20
Q4 FY25−$0.21n/a−$1.48
Q3 FY25−$0.36n/a−$1.80
Q2 FY25−$0.41n/a−$1.78
Q1 FY25−$0.50n/a−$1.77
Q4 FY24−$0.53n/a−$1.66
Q3 FY24−$0.34n/a−$1.55
Q2 FY24−$0.40n/a−$1.64
Q1 FY24−$0.39n/a−$1.62
Q4 FY23−$0.42n/a−$1.57
Q3 FY23−$0.43n/a−$1.46

Against its peers

Companies in Biotechnology nearest Recursion Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RXRXRecursion Pharmaceuticals−$1.04
VCELVericel$0.46+283% a year
ADMAAdma Biologics$0.70−18% a year
MGTXMeiraGTx$0.71
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
PLXProtalix BioTherapeutics$0.23+283% a year
Peer median$0.94

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Recursion Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.